Generation Bio Co. (NASDAQ:GBIO) Short Interest Up 16.3% in December

Generation Bio Co. (NASDAQ:GBIO - Get Free Report) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totalling 1,780,000 shares, a growth of 16.3% from the November 30th total of 1,530,000 shares. Based on an average trading volume of 223,300 shares, the short-interest ratio is currently 8.0 days. Currently, 4.2% of the company's stock are short sold.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC bought a new stake in shares of Generation Bio during the 3rd quarter worth about $42,000. Cubist Systematic Strategies LLC lifted its position in Generation Bio by 91.0% during the second quarter. Cubist Systematic Strategies LLC now owns 19,046 shares of the company's stock worth $54,000 after acquiring an additional 9,075 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Generation Bio by 199.3% during the second quarter. American Century Companies Inc. now owns 31,786 shares of the company's stock worth $90,000 after acquiring an additional 21,167 shares during the period. Barclays PLC grew its position in shares of Generation Bio by 165.5% in the third quarter. Barclays PLC now owns 76,430 shares of the company's stock valued at $189,000 after purchasing an additional 47,639 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Generation Bio by 7.4% during the second quarter. Rhumbline Advisers now owns 78,903 shares of the company's stock worth $222,000 after purchasing an additional 5,430 shares during the period. 95.22% of the stock is currently owned by institutional investors.

Generation Bio Stock Down 0.9 %

Shares of GBIO stock traded down $0.01 on Monday, reaching $1.06. The stock had a trading volume of 217,723 shares, compared to its average volume of 202,432. Generation Bio has a 12 month low of $0.75 and a 12 month high of $4.65. The firm has a market capitalization of $70.80 million, a price-to-earnings ratio of -0.48 and a beta of 2.66. The firm's 50-day moving average is $1.62 and its two-hundred day moving average is $2.27.

Analysts Set New Price Targets

Several research analysts recently commented on GBIO shares. Wedbush reissued an "outperform" rating and set a $5.00 price target on shares of Generation Bio in a research report on Thursday, November 7th. Needham & Company LLC reissued a "buy" rating and issued a $10.00 price objective on shares of Generation Bio in a report on Wednesday, October 23rd.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.